Although it was uncertain to determine whether there was any relation between anti-cyclin B1 and clinical outcome after radical prostatectomy surgery; because of the lack of further follow-up information on patients after surgery, anti-cyclin B1 autoantibody still might be a potential biomarker for the prognosis of PCa after surgery treatment. The gene discussed is CCNB1; the disease is posterior cortical atrophy.